StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Matinas BioPharma's profit margin for the twelve months ending Dec 31, 2023 was -2093.2%. For fiscal 2023 it was -2093.2%, against -658.6% the year before. The highest annual figure on record is -658.6% in fiscal 2022.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-2093.2%−1434.6
FY2022Dec 31, 2022-658.6%+69895.9
FY2021Dec 31, 2021-70554.5%−56377.6
FY2020Dec 31, 2020-14177.0%+5166.4
FY2019Dec 31, 2019-19343.4%−7583.0
FY2018Dec 31, 2018-11760.4%−1414.5
FY2017Dec 31, 2017-10345.9%−5648.9
FY2015Dec 31, 2015-4697.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2023Mar 31, 2023-503.0%+14366.1
Q4 FY2022Dec 31, 2022-341.9%+9803.5
Q3 FY2022Sep 30, 2022-513.8%+5172.6
Q2 FY2022Jun 30, 2022-557.2%+3166.9
Q1 FY2021Mar 31, 2021-14869.1%−11071.2
Q4 FY2020Dec 31, 2020-10145.4%+3583.4
Q3 FY2020Sep 30, 2020-5686.5%+2392.7
Q2 FY2019Jun 30, 2019-3724.1%+3835.5
Q2 FY2018Jun 30, 2018-3797.9%+5037.5
Q1 FY2018Mar 31, 2018-13728.8%+16307.3
Q4 FY2017Dec 31, 2017-8079.1%–
Q3 FY2017Sep 30, 2017-7559.6%–
Q2 FY2017Jun 30, 2017-8835.4%–
Q1 FY2017Mar 31, 2017-30036.2%–

More Matinas BioPharma figures

See a number that looks wrong?